New Therapeutic Options for Fusariosis: A Patent Review (2008–2023)

TL;DR

This paper reviews recent patents for treating Fusariosis, a fungal infection, and highlights the need for new therapies due to rising antifungal resistance.

Contribution

The study provides a comprehensive analysis of patents and scientific publications on Fusariosis treatments from 2008 to 2023.

Findings

21 patents specifically targeted Fusarium infections in humans between 2008 and 2023.

Patents explored mechanisms like drug delivery, gene expression, and novel compounds.

2014 and 2018 had the highest number of patents, with three each, while the average annual scientific articles were 58.

Abstract

Fusariosis is an infection caused by the fungus Fusarium spp., which is pathogenic to both plants and humans. The disease presents several clinical manifestations and epidemiological patterns. Current treatment relies on azoles and polyenes, but increasing antifungal resistance requires the exploration of new therapeutic options. This study reviewed patents related to the treatment of Fusariosis from the last 15 years (up to June 2023). The search identified 318 patents, categorized by identification code, publication date, type of application and mechanism of action, using the International Patent Classification and Cooperative Patent Classification systems. In addition, we conducted a bibliographic search in the PubMed database using the same criteria to identify the number of scientific articles. Of the 318 patents, 21 targeted Fusarium infections in humans. The years 2014 and 2018 stood out with three patents each, while the same period recorded an average of 58 published articles. The patents addressed mechanisms such as drug delivery, gene expression, immunotherapy, engineered drugs, and novel compounds. This research highlights the urgent need for continued innovation in therapeutic technologies to effectively treat Fusarium wilt.

Figures